ArticleHepatology (Baltimore, Md.)2008
Mechanisms of action of interferon and ribavirin in chronic hepatitis C: Summary of a workshop.
Abstract readConference Proceedings
In one paragraph
Article in Hepatology (Baltimore, Md.), 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
3.1field-weighted citation impact, top 9% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 91 citations in OpenAlex.
- Chrono-optimal treatments for human immunodeficiency virus/hepatitis C virus co-infection yield comparable survival outcomes with hepatitis C virus mono-infection.World journal of gastroenterology · 2026Article
- Review
- Direct antiviral agents (DAAs) and their use in pregnant women with hepatitis C (HCV).Expert review of anti-infective therapy · 2022Review
- Review
- A Focused Review on Recent Advances in the Diagnosis and Treatment of Viral Hepatitis.Gastroenterology research · 2021Review
- Host-Directed Antiviral Therapy.Clinical microbiology reviews · 2020Review
- Plasma FABP4 is associated with liver disease recovery during treatment-induced clearance of chronic HCV infection.Scientific reports · 2020Article
- Interferon-α-induced retinopathy in chronic hepatitis C treatment: summary, considerations, and recommendations.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2019Review
- Assessing Racial Disparities in HCV Infection and Care Outcomes in a Southern Urban Population.Journal of racial and ethnic health disparities · 2018Article
- A prediction model for the grade of liver fibrosis using magnetic resonance elastography.BMC gastroenterology · 2017Article
- Development of High-Throughput Screening Assay for Antihantaviral Therapeutics.SLAS discovery : advancing life sciences R & D · 2017Article
- Immunosuppression as a Possible Risk Factor for Interferon Nonresponse in Ocular Surface Squamous Neoplasia.Cornea · 2017Article
- Monitoring the treatment of hepatitis C with directly acting antivirals by serological and molecular methods.PloS one · 2017Article
- Immobilization of Neutral Protease from Bacillus subtilis for Regioselective Hydrolysis of Acetylated Nucleosides: Application to Capecitabine Synthesis.Molecules (Basel, Switzerland) · 2016Article
- Mutagenic Effects of Ribavirin on Hepatitis E Virus-Viral Extinction versus Selection of Fitness-Enhancing Mutations.Viruses · 2016Review
- Safety and Efficacy of Adding Ribavirin to Interferon or Peginterferon in Treatment of Hepatitis C Infection in Patients With Thalassemia: A Systematic Review on Randomized Controlled Trials.Hepatitis monthly · 2016Review
- Combinations of siRNAs against La Autoantigen with NS5B or hVAP-A Have Additive Effect on Inhibition of HCV Replication.Hepatitis research and treatment · 2016Article
- Effects of an 11-nm DMSA-coated iron nanoparticle on the gene expression profile of two human cell lines, THP-1 and HepG2.Journal of nanobiotechnology · 2015Article
- Ribavirin induced hemolysis: a novel mechanism of action against chronic hepatitis C virus infection.World journal of gastroenterology · 2014Review
- What is the future of ribavirin therapy for hepatitis C?Antiviral research · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 1 country.
Raymond T ChungMassachusetts General Hospital and Harvard Medical School, Boston, MA, USA. rtchung@partners.org
Michael Gale
Stephen J Polyak
Stanley M Lemon
T Jake Liang
Jay H Hoofnagle
University of Washington · USMassachusetts General Hospital · USNational Institute of Diabetes and Digestive and Kidney Diseases · USNational Institutes of Health · USThe University of Texas Medical Branch at Galveston · US
Funding
Therapy, Vaccine and Model Development in Viral Hepatitis and Liver DiseasesZIADK054505 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI LIANG, T. JAKE · 2009 to 2025
$17.5MVirus-Host Interactions in Hepatitis C Virus (HCV) InfectionsU19AI040035 · NIAID · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI THOMAS, DAVID L · 1996 to 2009
$12.0MStudies of HCV Infection, Vaccine Development and HCV-Host interactionsZIADK054504 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI LIANG, T. JAKE · 2009 to 2022
$12.0MSuppression of HCV-specific CD4+ T Cells by Core ProteinU19AI066328 · NIAID · UNIVERSITY OF COLORADO DENVER · PI ROSEN, HUGO RAMON · 2005 to 2014
$6.8MThe Host Response to Hepatitis C VirusR01AI060389 · NIAID · UT SOUTHWESTERN MEDICAL CENTER · PI GALE, MICHAEL · 2003 to 2012
$3.4MHIV-Hepatitis C Virus Interactions and PathogenesisR01AI069939 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI CHUNG, RAYMOND T · 2006 to 2010
$1.9MHepatitis C Virus Induced IL-8 &Inhibition of InterferonR01DK062187 · NIDDK · UNIVERSITY OF WASHINGTON · PI POLYAK, STEPHEN J. · 2003 to 2007
$1.4MNS5A GENE PRODUCT &MECHANISM OF HEPATITIS C VIRUS INTERFERON RESISTANCEZ01DK054505 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI LIANG, T. JAKE · 1997 to 2008
$1.0MTRANSGENIC MOUSE MODEL FOR STUDY OF VIRAL HEPATITIS CZ01DK054504 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI LIANG, T. JAKE · 1997 to 2008
$1.0MThe Host Response to Hepatitis C VirusR56AI060389 · NIAID · UNIVERSITY OF WASHINGTON · PI GALE, MICHAEL · 2014 to 2014
$494kIntramural NIH HHS Z01 DK054504Intramural NIH HHS Z01 DK054505Intramural NIH HHS Z99 DK999999Intramural NIH HHS ZIA DK054504Intramural NIH HHS ZIA DK054505NIAID NIH HHS AI060389NIAID NIH HHS AI066328NIAID NIH HHS AI069939NIAID NIH HHS R01 AI060389NIAID NIH HHS R01 AI069939NIAID NIH HHS R56 AI060389NIAID NIH HHS U19 AI040035NIAID NIH HHS U19 AI066328NIAID NIH HHS U19-AI40035NIDDK NIH HHS DK062187NIDDK NIH HHS DK078722NIDDK NIH HHS R01 DK062187
Abstract
PubMed holds no abstract for this paper.
Indexed as
Antiviral AgentsGene ExpressionHepacivirusHepatitis C, ChronicHumansInterferonsRibavirinTreatment OutcomeAntiviral AgentsInterferonsRibavirin
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.